Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 4 Medical Devices Recommended for Approval
October 26, 2009
- NHI Price Revision Rate, Policy to Be Proposed by Panel under Health Minister
October 26, 2009
- NEW PRODUCTS／Yakuban Tape 60 mg to Be Launched in December
October 26, 2009
- JMA Demands Increases in Medical Fees
October 26, 2009
- 32nd JSH Annual Scientific Meeting
October 26, 2009
- Forum Attendants Express Concern about Rising Dispensing Fees
October 26, 2009
- Findings from Evista's 3-Year PMS Reported
October 26, 2009
- No Mention Made on Development of Drugs at Korosho Policy Conference
October 26, 2009
- Blood Sugar Control Improved in Diabetes Patients Switching to Liraglutide: Novo Nordisk
October 26, 2009
- New Administration Route Approved for Temodal
October 26, 2009
- Incretin Therapy Suitable for Japanese Patients with Diabetes: Dr Seino
October 26, 2009
- REGULATORY NEWS IN BRIEF
October 26, 2009
- Biogen Idec Japan Aims at 50% Share in Market for IFN-b
October 26, 2009
- Shionogi Allies with UK Universities, Bioventures for Drug Discovery
October 26, 2009
- Rasilez May Become Blockbuster: T. Rosenberg, Novartis
October 26, 2009
- Life Science Degrades to 2nd Place in Priority Science and Technology Ranking
October 26, 2009
- Datamonitor Predicts that Acquisition of Solvay Will Have Positive Effects on Abbott
October 26, 2009
- R＆D NEWS IN BRIEF
October 26, 2009
- Additional Safety Information to Be Provided on Obescare
October 19, 2009
- GSK, Novartis Contract with Korosho to Supply Flu Vaccines
October 19, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…